Nick Pizzie
Known title: CHIEF FINANCIAL OFFICERCIK: 0001742143
Nick Pizzie's purchase track record
Nick Pizzie has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/18/2021 | AXSM | $34K | -14.5% | -11.5% | -17.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AXSM | ▲ Buy | Option Exercise | 33,000 | $116K | 6/9/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 33,000 | $7.9M | 6/9/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 12,000 | $42K | 1/22/2026 | View on chart |
| AXSM | ▼ Sell | Open Market | 12,000 | $2.3M | 1/22/2026 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 3,000 | $11K | 2/14/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 3,000 | $393K | 2/14/2025 | View on chart |
| AXSM | ▲ Buy | Option Exercise | 12,000 | $42K | 2/13/2025 | View on chart |
| AXSM | ▼ Sell | Open Market | 12,000 | $1.6M | 2/13/2025 | View on chart |
| AXSM | ▲ Buy | Open Market | 527 | $19K | 11/18/2021 | View on chart |
| AXSM | ▲ Buy | Open Market | 141 | $5K | 11/18/2021 | View on chart |
| AXSM | ▲ Buy | Open Market | 145 | $5K | 11/18/2021 | View on chart |
| AXSM | ▲ Buy | Open Market | 142 | $5K | 11/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Deutsche Bank cuts Axsome Therapeutics price target to $267
Deutsche Bank maintained its positive stance on Axsome Therapeutics but lowered its price target to $267. This adjustment comes as the stock trades near a key support level, with recent technical signals indicating a rejection at that price point. While other analysts continue to highlight the company's potential, the latest target remains below the current average analyst estimate.
Deutsche Bank cuts Axsome Therapeutics price target to $267. Deutsche Bank maintained its positive stance on Axsome Therapeutics but lowered its price target to $267. This adjustment comes as the stock trades near a key support level, with recent technical signals indicating a rejection at that price point. While other analysts continue to highlight the company's potential, the latest target remains below the current average analyst estimate.